Clinical Trial Update: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial (CodeBreaK 202) comparing a sotorasib-platinum doublet to a pembrolizumab-platinum doublet as first-line therapy for stage IV or adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LUMAKRAS (sotorasib)

Snippet

Sponsor: Amgen | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING